- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 40/30 - Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
Patent holdings for IPC class A61K 40/30
Total number of patents in this class: 223
10-year publication summary
|
4
|
10
|
11
|
27
|
22
|
20
|
27
|
7
|
38
|
43
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Trustees of the University of Pennsylvania | 4435 |
8 |
| The Regents of the University of California | 20868 |
7 |
| The Board of Trustees of the Leland Stanford Junior University | 6707 |
7 |
| Allogene Therapeutics, Inc. | 167 |
6 |
| Immunitybio, Inc. | 513 |
6 |
| FATE Therapeutics, Inc. | 237 |
5 |
| Kite Pharma, Inc. | 457 |
5 |
| Memorial Sloan-Kettering Cancer Center | 2058 |
5 |
| Poseida Therapeutics, Inc. | 174 |
4 |
| Baylor College of Medicine | 1013 |
3 |
| King's College London | 572 |
3 |
| Umoja Biopharma, Inc. | 70 |
3 |
| Adicet Therapeutics, Inc. | 43 |
3 |
| University of Florida Research Foundation, Inc. | 4194 |
2 |
| Northwestern University | 3567 |
2 |
| Cellectis | 415 |
2 |
| The Children's Hospital of Philadelphia | 872 |
2 |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | 1036 |
2 |
| Hospital Clinic de Barcelona | 143 |
2 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 3295 |
2 |
| Other owners | 144 |